SCHEMBL2977271

SCHEMBL2977271

CC[C@@](O)(c1cnc(Sc2ccc3c(-c4ccccc4)cc(=O)oc3c2)s1)C(F)(F)F

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MLYCD O95822 2/20 0.57
ALOX5 P09917 4/20 0.52
ALDH1A1 P00352 6/20 0.41
HPGD P15428 6/20 0.41
USP2 O75604 1/20 0.41
MAOB P27338 2/20 0.41
AKR1B1 P15121 2/20 0.41
CA12 O43570 1/20 0.41
ALDH2 P05091 1/20 0.41
MAOA P21397 1/20 0.41
HSD17B3 P37058 1/20 0.41
SORD Q00796 1/20 0.41
CA9 Q16790 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
KMT2A Q03164 2/20 0.39
KDM4E B2RXH2 1/20 0.38
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38
RECQL P46063 1/20 0.38
MCL1 Q07820 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2977269 1.00 MLYCD (0.57) MLYCDALOX5ALDH1A1HPGDUSP2
SCHEMBL2983229 0.93 MLYCD (0.55) MLYCDALOX5ALDH1A1HPGDUSP2
SCHEMBL2989716 0.93 MLYCD (0.55) MLYCDALOX5ALDH1A1HPGDUSP2
SCHEMBL2979837 0.92 MLYCD (0.57) MLYCDALOX5ALDH1A1HPGDCA12
SCHEMBL2987497 0.92 MLYCD (0.57) MLYCDALOX5ALDH1A1HPGDCA12
SCHEMBL2985044 0.92 MLYCD (0.57) MLYCDALOX5ALDH1A1HPGDCA12
SCHEMBL2983994 0.92 MLYCD (0.55) MLYCDALOX5ALDH1A1HPGDUSP2
SCHEMBL2983995 0.92 MLYCD (0.55) MLYCDALOX5ALDH1A1HPGDUSP2
SCHEMBL2979616 0.91 MLYCD (0.57) MLYCDALOX5ALDH1A1HPGDUSP2
SCHEMBL2982046 0.91 MLYCD (0.57) MLYCDALOX5ALDH1A1HPGDUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7439260-B2 7-(1,3-thiazol-2-YL)thio-coumarin derivatives and their use as leukotriene biosynthesis inhibitors MERCK FORSST CANADA & CO. (CA) 2008-10-21 US claimed
US-20060116406-A1 7-(1,3-thiazol-2-yl)thio!-coumarin derivatives and their use as leukotriene biosynthesis inhibitors GAREAU YVES 2006-06-01 US claimed
US-20100137371-A1 Novel Pharmaceutical Compounds MERCK FROSST CANADA LTD. (CA) 2010-06-03 US disclosed
US-20100137371-A1 Novel Pharmaceutical Compounds MERCK FROSST CANADA LTD. (CA) 2010-06-03 US disclosed
US-20100137371-A1 Novel Pharmaceutical Compounds MERCK FROSST CANADA LTD. (CA) 2010-06-03 US disclosed
US-7439260-B2 7-(1,3-thiazol-2-YL)thio-coumarin derivatives and their use as leukotriene biosynthesis inhibitors MERCK FORSST CANADA & CO. (CA) 2008-10-21 US disclosed
US-7439260-B2 7-(1,3-thiazol-2-YL)thio-coumarin derivatives and their use as leukotriene biosynthesis inhibitors MERCK FORSST CANADA & CO. (CA) 2008-10-21 US disclosed
US-7439260-B2 7-(1,3-thiazol-2-YL)thio-coumarin derivatives and their use as leukotriene biosynthesis inhibitors MERCK FORSST CANADA & CO. (CA) 2008-10-21 US disclosed
US-20060116406-A1 7-(1,3-thiazol-2-yl)thio!-coumarin derivatives and their use as leukotriene biosynthesis inhibitors GAREAU YVES 2006-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060116406-A1 7-(1,3-thiazol-2-yl)thio!-coumarin derivatives and their use as leukotriene biosynthesis inhibitors LTC4S, LTA4H, CYSLTR1 MLYCD 2142/4885ALOX5 17/4885ALDH1A1 123/4885
US-20100137371-A1 Novel Pharmaceutical Compounds LTC4S, LTA4H, LTB4R2 MLYCD 2597/4885ALOX5 17/4885ALDH1A1 232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.